Table 1 Basic characteristics of all patients and patients stratified according to their 25(OH)D3 plasma level, menopausal status, and tumor CYP27B1 level.
From: Vitamin D3 reduces the expression of M1 and M2 macrophage markers in breast cancer patients
Parameter | All patients | 25(OH)D3 concentration | Menopausal status | CYP27B1 expression | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Normal | Deficient | P | Pre | Post | P | Low | High | P | |||
Age | N | 127 | 38 | 89 | 38 | 89 | 40 | 39 | |||
(years) | 60 (31–85) | 56 (31–83) | 63 (32–85) | 0.088 | 47 (31–70) | 66 (44–85) | < 0.0001 | 57 (32–83) | 60 (35–83) | 0.318 | |
BMI | N | 120 | 36 | 84 | 35 | 85 | 37 | 38 | |||
(kg/m2) | 26.8 (16.5–42.5) | 25.6 (16.5–36.1) | 27.9 (18.5–42.5) | 0.002 | 23.4 (16.5–40.4) | 28.1 (17.2–42.5) | < 0.0001 | 26.8 (16.5–40.3) | 27.0 (17.2–38.0) | 0.864 | |
25(OH)D3 | N | 127 | 38 | 89 | 38 | 89 | 40 | ||||
(ng/mL) | 23.2 (2.0–67.7) | 39.3 (31.3–67.7) | 19.6 (2.0–29.2) | < 0.0001 | 23.7 (11.5–50.4) | 21.5 (2.0–67.7) | 0.056 | 21.1 (7.1–60.1) | 23.1 (2.0–42.8) | 0.874 | |
FSH | N | 126 | 38 | 88 | 38 | 88 | 40 | 38 | |||
(mIU/mL) | 58 (2.4–154) | 54.9 (2.5–154) | 59.2 (2.4–138) | 0.551 | 6.9 (2.4–82.3) | 70 (4–154) | < 0.0001 | 42.2 (2.4–97.6) | 54.1 (2.5–154) | 0.460 | |
Estradiol | N | 127 | 38 | 89 | 38 | 89 | 40 | 38 | |||
(pg/mL) | 14 (4–617) | 15 (4–574) | 14 (4–617) | 0.848 | 94 (22–617) | 8 (4–40) | < 0.0001 | 17 (4–617) | 14 (4–390) | 0.926 | |
PTH | N | 127 | 38 | 89 | 38 | 89 | 40 | 39 | |||
(pg/mL) | 30.4 (18–230) | 29.0 (18.0–53.7) | 32 (18.5–230) | 0.007 | 28.5 (18.5–58.6) | 33 (18–230) | 0.009 | 31.1 (18.5–52.8) | 29.6 (18.5–62.1) | 0.890 | |
Statistical analysis: Mann‒Whitney test. | |||||||||||
